We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Slowly but surely, Australia’s Prescient Therapeutics is getting its lead cancer program back on track, with two of three trials subject to an FDA clinical hold now cleared to resume.